|D009362||Neoplasm Metastasis NIH||0.71|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
There is one clinical trial.
Study conducted on hospitalized patient in critical ill units in Nancy and Metz to evaluate if early corticosteroid treatment in first seven days after admission improve patients outcome in Acute Respiratory Distress Syndrome secondary to Covid-19 compared to later corticosteroid therapy or no treatment. Also comparison of acquired infection with or without corticosteroid treatment during hospitalisation.
Description: Mortality rates in ICU in each groupMeasure: Mortality in ICU Time: within ICU stay, on average 15 days
Description: mortality at day 28 after ICU admissionMeasure: Mortality d28 Time: 28 days
Description: cumulative incidence of infection acquired during ICU stayMeasure: acquired infections incidence Time: 28 days
Description: number of treatment days with antibiotics during ICU stayMeasure: antibiotics duration Time: 28 days
Description: number of days of treatment by mechanical ventilation during ICU stayMeasure: mechanical ventilation duration Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports